Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC. Lim SM, Lee JB, Cho BC. J Thorac Oncol 2024;19:376-379.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lim SM, Lee JB, Cho BC. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC. J Thorac Oncol 2024;19:376-379.
PMID: 38453325